Profund Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Profund Advisors’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-32,547	Closed	-$1.33M	–	1165
2024 Q2	$1.33M	Sell	32,547 -2,687	-8%	-$112K	0.05%	250
2024 Q1	$1.49M	Buy	35,234 +11,209	+47%	+$471K	0.06%	230
2023 Q4	$1.02M	Sell	24,025 -9,959	-29%	-$286K	0.04%	326
2023 Q3	$742K	Buy	33,984 +1,379	+4%	+$34.5K	0.04%	356
2023 Q2	$1.04M	Sell	32,605 -6,711	-17%	-$206K	0.06%	309
2023 Q1	$959K	Buy	+39,316	New	+$1.15M	0.06%	311

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Profund Advisors's CERE Position: Q3 2024 in Review

Profund Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 32,547 shares — an estimated $1.33M sold.

Profund Advisors first reported a position in CERE in Q1 2023 and held it in 6 quarters. The position peaked at $1.49M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Profund Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Profund Advisors sold 32,547 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $1.33M.
Profund Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2023 and held it in 6 quarters.
Profund Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.49M in Q1 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Profund Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.